Meloxicam-1- d -MT Dual-Drug Hydrogel Serves as an Immunomodulator to Reverse Tumor Postoperative Recurrence and Metastasis

Key Points

• To assess the effectiveness of a dual-drug hydrogel in reversing tumor recurrence and metastasis after surgery.
• Utilized a meloxicam-1-d-mt dual-drug hydrogel postoperatively.
• Evaluated T cell activity and levels of antitumor cytokines such as interferon-γ.
• Analyzed the reduction of residual tumor burden and recurrence risk.
• Demonstrated increased T cell activity post-application of the hydrogel.
• Showed elevated levels of interferon-γ following treatment.
• Reduced risk of tumor recurrence and metastasis after tumor resection.